# Advances in Breast Cancer Research: Immunological, Pathological, and Pharmacological Perspectives for Improving Patient Outcomes

## TL;DR

This paper reviews recent advances in breast cancer research, focusing on immune, diagnostic, and treatment innovations to improve patient outcomes globally.

## Contribution

The paper synthesizes current global research on breast cancer, emphasizing new diagnostic technologies and therapies.

## Key findings

- Digital pathology and AI are redefining tumor characterization.
- Immunotherapy and targeted agents are transforming treatment approaches.
- Disparities in access to advanced care persist between high-income and LMICs.

## Abstract

Breast cancer remains the most frequently diagnosed malignancy worldwide. Over the past decade, advances in molecular biology have expanded beyond tumor-intrinsic features to encompass the immune microenvironment and patient-specific pharmacogenomic profiles, profoundly reshaping diagnostic, prognostic, and therapeutic paradigms in breast oncology. Owing to rapid technological progress and an expanding therapeutic armamentarium, periodic synthesis of both foundational principles and emerging evidence remains essential for the critical interpretation of ongoing advances. This review provides a comprehensive overview of the contemporary global landscape of breast cancer, integrating developments in diagnosis, risk stratification, and therapeutic innovation. We examine the emerging technologies that are redefining tumor characterization, including digital pathology, artificial intelligence-assisted morphological and molecular analyses, and advanced molecular profiling approaches that increasingly inform prognostic and predictive assessment. We further discuss how these diagnostic frameworks are translating into therapeutic advances, with emphasis on immunotherapy, antibody-drug conjugates, mutation-directed targeted agents, therapeutic vaccines, and bispecific antibodies. Collectively, these developments highlight key translational research priorities, support evidence-based clinical decision-making, and explicitly acknowledge disparities in access and implementation between high-income settings and low- and middle-income countries (LMICs).